T1	Pharmacological_substance 738 752	corticosteroid
T2	GGPs 1483 1488	CCL13
T4	Artificial_process 1221 1230	treatment
T7	Localization 906 913	secrete
T10	Disorder 854 860	asthma
T15	GGPs 1476 1481	CCL17
T17	Cell 886 902	epithelial cells
T18	GGPs 765 774	Periostin
T20	Disorder 258 271	severe asthma
T22	GGPs 1400 1409	periostin
T23	Anatomical_entity 876 885	bronchial
T24	Anatomical_entity 970 976	airway
T25	Anatomical_entity 573 579;602 609	sputum samples
T29	Disorder 1254 1260	asthma
T30	Disorder 102 108	asthma
T31	GGPs 944 953	biomarker
T32	Pharmacological_substance 1278 1290	Lebrikizumab
T38	Artificial_process 322 329	therapy
T39	Subject 1083 1093	asthmatics
T43	Subject 1445 1453	subgroup
T44	Anatomical_entity 1470 1475	Serum
T45	GGPs 8 17	periostin
T46	Subject 244 252	Patients
T47	Entity_Property 1234 1240	severe
T48	Pharmacological_substance 1527 1539	lebrikizumab
T50	Negative_regulation 1370 1379	reduction
T51	GGPs 1009 1028	monoclonal antibody
T56	Artificial_process 354 363	treatment
T60	Disorder 513 542	idiopathic pulmonary fibrosis
T61	Disorder 815 837	subepithelial fibrosis
T63	Pharmacological_substance 1044 1056	Lebrikizumab
T66	Pharmacological_substance 1176 1191	corticosteroids
T72	GGPs 925 934	Periostin
T73	Pharmacological_substance 683 698	corticosteroids
T77	GGPs 1435 1444	periostin
T78	Pharmacological_substance 991 1003	Lebrikizumab
T82	Disorder 125 131	Asthma
T86	GGPs 914 923	periostin
T87	Disorder 505 511	asthma
T90	Subject 1410 1418	subgroup
E1	Artificial_process:T4 disorder:T9
E2	Localization:T7 Theme:T86 fromLoc:T17
E4	Artificial_process:T38 
E5	Negative_regulation:T50 Theme:T68
E7	Artificial_process:T56 
N8	Reference T2 UMLS:C0390071	Monocyte Chemoattractant Protein 4
N21	Reference E1 UMLS:C0087111	Therapeutic procedure
N45	Reference T10 UMLS:C0004096	Asthma
N71	Reference T17 UMLS:C0014597	Epithelial Cells
N80	Reference T18 UMLS:C0219433	POSTN protein, human
N85	Reference T20 UMLS:C0581126	Severe asthma
N95	Reference T22 UMLS:C0219433	POSTN protein, human
N103	Reference T24 UMLS:C0458827	Airway structure
N120	Reference T29 UMLS:C0004096	Asthma
N124	Reference T30 UMLS:C0004096	Asthma
N127	Reference T31 UMLS:C0005516	Biological Markers
N130	Reference T32 UMLS:C2981360	lebrikizumab
N151	Reference E4 UMLS:C0087111	Therapeutic procedure
N153	Reference T39 UMLS:C3816164	Asthmatics
N177	Reference T44 UMLS:C0229671	Serum
N183	Reference T45 UMLS:C0219433	POSTN protein, human
N185	Reference T46 UMLS:C0030705	Patients
N187	Reference T47 UMLS:C0205082	Severe (severity modifier)
N194	Reference T48 UMLS:C2981360	lebrikizumab
N214	Reference T51 UMLS:C0003250	Monoclonal Antibodies
N241	Reference E7 UMLS:C0087111	Therapeutic procedure
N259	Reference T60 UMLS:C1800706	Idiopathic Pulmonary Fibrosis
N262	Reference T61 UMLS:C3553304	Subepithelial fibrosis
N268	Reference T63 UMLS:C2981360	lebrikizumab
N308	Reference T72 UMLS:C0219433	POSTN protein, human
N315	Reference T73 UMLS:C0001617	Adrenal Cortex Hormones
N339	Reference T77 UMLS:C0219433	POSTN protein, human
N343	Reference T78 UMLS:C2981360	lebrikizumab
N353	Reference T82 UMLS:C0004096	Asthma
N366	Reference T86 UMLS:C0219433	POSTN protein, human
N370	Reference T87 UMLS:C0004096	Asthma
T93	Disorder 547 551	COPD
T92	Biological_process 977 989	inflammation
E10	Biological_process:T92 atLoc:T24
N2	Reference E10 UMLS:C0021368	Inflammation
T94	Biological_process 489 501	pathogenesis
E11	Biological_process:T94 Theme:T93
N4	Reference E11 UMLS:C0699748	Pathogenesis
T96	Disorder 423 438	allergic asthma
N14	Reference T96 UMLS:C0155877	Allergic asthma
N1	Reference T93 UMLS:C0024117	Chronic Obstructive Airway Disease
T80	Disorder 629 642	severe asthma
N9	Reference T80 UMLS:C0581126	Severe asthma
T98	Biological_process 1066 1079	lung function
E8	Biological_process:T98 Theme:T39
N20	Reference E8 UMLS:C0035245	Respiratory physiology
T79	Subject 1540 1545	group
N23	Reference T79 UMLS:C1257890	Population Group
T54	GGPs 796 801	TGF-β
N25	Reference T54 UMLS:C0040690	Transforming Growth Factor beta
T65	GGPs 77 81	IL-4
N27	Reference T65 UMLS:C0021758	Interleukin-4
T69	GGPs 25 30	IL-13
N28	Reference T69 UMLS:C0214743	Interleukin-13
T70	GGPs 51 56	IL-13
N29	Reference T70 UMLS:C0214743	Interleukin-13
T99	GGPs 82 87	IL-13
N30	Reference T99 UMLS:C0214743	Interleukin-13
T100	GGPs 376 381	IL-13
N33	Reference T100 UMLS:C0214743	Interleukin-13
T101	GGPs 456 461	IL-13
N36	Reference T101 UMLS:C0214743	Interleukin-13
T102	GGPs 553 558	IL-13
N39	Reference T102 UMLS:C0214743	Interleukin-13
T103	GGPs 706 711	IL-13
N41	Reference T103 UMLS:C0214743	Interleukin-13
T104	GGPs 862 867	IL-13
N42	Reference T104 UMLS:C0214743	Interleukin-13
T105	GGPs 1037 1042	IL-13
N43	Reference T105 UMLS:C0214743	Interleukin-13
T106	GGPs 1297 1302	IL-13
N44	Reference T106 UMLS:C0214743	Interleukin-13
T107	Cell 958 961	Th2
N46	Reference T107 UMLS:C0242633	T-helper cell type 2
R2	Disorder_association Arg1:T61 Arg2:T10	
T16	Measurement 19 23	FENO
T68	Measurement 1383 1387	FENO
T109	Pharmacological_substance 32 43	lebrikzumab
N6	Reference T109 UMLS:C2981360	lebrikizumab
T49	Negative_regulation 1291 1296	block
E12	Negative_regulation:T49 Cause:T32 Theme:E14
N48	Reference E12 UMLS:C3463820	Inhibition
N3	Reference T1 UMLS:C0001617	Adrenal Cortex Hormones
N5	Reference T66 UMLS:C0001617	Adrenal Cortex Hormones
T111	Pathway 1297 1312	IL-13 signaling
E14	Pathway:T111 Participant:T106 Participant2:T40
N52	Reference E14 UMLS:C3158959	interleukin-13-mediated signaling pathway
T113	GGPs 1325 1333	IL-13Rα1
N55	Reference T113 UMLS:C0527729	Interleukin-13 Receptor alpha1 Subunit
T114	GGPs 1334 1340	IL-4Rα
N56	Reference T114 UMLS:C1721038	Interleukin-4 Receptor alpha Subunit
T40	GGPs 1325 1349	IL-13Rα1/IL-4Rα receptor
N57	Reference T40 UMLS:C1721037	Receptors, Interleukin-4, Type II
R3	part_of Arg1:T113 Arg2:T40	
R4	part_of Arg1:T114 Arg2:T40	
T115	GGPs 1499 1502	IgE
N10	Reference T115 UMLS:C0020846	Immunoglobulin E
N59	Reference T15 UMLS:C1959608	Chemokine CCL17
N61	Reference T23 UMLS:C0006255	Bronchi
N63	Reference E5 UMLS:C3463820	Inhibition
T118	Positive_regulation 868 875	induces
E16	Positive_regulation:T118 Cause:T104 Theme:E2
N64	Reference E16 UMLS:C1879547	Activation action
T119	Positive_regulation 962 969	induced
E17	Positive_regulation:T119 Cause:T107 Theme:E10
N65	Reference E17 UMLS:C1879547	Activation action
T120	Correlation 726 734	involved
E18	Correlation:T120 Theme:T103 Theme2:E22
N66	Reference E18 UMLS:C0332281	Associated with
T121	Positive_regulation 775 783	enhances
E19	Positive_regulation:T121 Cause:T18 Theme:E26 disorder:T61
N67	Reference E19 UMLS:C1879547	Activation action
T122	Positive_regulation 617 625	elevated
E20	Positive_regulation:T122 Theme:E24 disorder:T80
T123	Negative_regulation 1510 1519	decreased
E21	Negative_regulation:T123 Theme:E25 atLoc:T44
N69	Reference E21 UMLS:C3463820	Inhibition
T37	Biological_process 753 763	resistance
E22	Biological_process:T37 Cause:T1
T124	Positive_regulation 1057 1065	improved
E23	Positive_regulation:T124 Cause:T63 Theme:E8
N72	Reference E23 UMLS:C1879547	Activation action
T125	Gene_expression 559 565	levels
E24	Gene_expression:T125 Theme:T102 atLoc:T27
N73	Reference E24 UMLS:C1519614	Genetic Translation Process
T14	Gene_expression 1503 1509	levels
E25	Gene_expression:T14 Theme:T115
N58	Reference E25 UMLS:C1519614	Genetic Translation Process
T89	Pathway 796 811	TGF-β signaling
E26	Pathway:T89 Participant:T54
T126	Negative_regulation 57 67	antagonist
E27	Negative_regulation:T126 Theme:T70
N75	Reference E27 UMLS:C3463820	Inhibition
T62	Negative_regulation 88 98	antagonist
E28	Negative_regulation:T62 Theme:T65 Theme2:T99
N76	Reference E28 UMLS:C3463820	Inhibition
N31	Reference E2 UMLS:C0036536	Process of secretion
N70	Reference E22 UMLS:C0013203	Drug resistance
R5	Subject_Disorder Arg1:T46 Arg2:T20	
T58	Pharmacological_substance 1151 1163	beta agonist
N16	Reference T58 UMLS:C0001644	Adrenergic beta-Agonists
N18	Reference T90 UMLS:C2347789	Clinical Study Population Subgroup
N19	Reference T43 UMLS:C2347789	Clinical Study Population Subgroup
T9	Disorder 1234 1240;1254 1260	severe asthma
N22	Reference T9 UMLS:C0581126	Severe asthma
R8	member_of Arg1:T9 Arg2:T29	
T11	Positive_regulation 411 419	mediator
E3	Positive_regulation:T11 Cause:T100 Theme:T96 Cue:T19
N7	Reference E3 UMLS:C1879547	Activation action
E9	Gene_expression:T125 Theme:T102 atLoc:T25
N12	Reference E9 UMLS:C1519614	Genetic Translation Process
E13	Positive_regulation:T122 Theme:E9 disorder:T80
R9	part_of Arg1:T17 Arg2:T23	
R10	member_of Arg1:T78 Arg2:T13	
E6	Biological_process:T94 Theme:T60
N17	Reference E6 UMLS:C0699748	Pathogenesis
E15	Biological_process:T94 Theme:T87
N24	Reference E15 UMLS:C0699748	Pathogenesis
T6	Artificial_process 1123 1132	treatment
E30	Artificial_process:T6 Instrument:T58 Instrument2:T66 Theme:T39
E32	Gene_expression:T14 Theme:T2
N37	Reference E32 UMLS:C1519614	Genetic Translation Process
E33	Gene_expression:T14 Theme:T15
N38	Reference E33 UMLS:C1519614	Genetic Translation Process
E34	Negative_regulation:T123 Theme:E33 atLoc:T44
N40	Reference E34 UMLS:C3463820	Inhibition
E35	Negative_regulation:T123 Theme:E32 atLoc:T44
N47	Reference E35 UMLS:C3463820	Inhibition
T12	Biological_process 784 795	profibrotic
E36	Biological_process:T12 Cause:E26
N49	Reference E36 UMLS:C0596570	fibrogenesis
T27	Anatomical_entity 584 609	bronchial  biopsy samples
N50	Reference T27 UMLS:C0586650	Bronchial biopsy sample
N51	Reference T25 UMLS:C0444159	Sputum specimen
T19	Speculation_cue 386 398	demonstrated
A1	Speculated E3
R1	part_of Arg1:T44 Arg2:T79	
T13	GGPs 1009 1042	monoclonal antibody against IL-13
R6	member_of Arg1:T13 Arg2:T51	
N13	Reference E26 UMLS:C1515163	TGF Beta Signaling Pathway BioCarta
N15	Reference E13 UMLS:C1879547	Activation action
N35	Reference E20 UMLS:C1879547	Activation action
N34	Reference E30 UMLS:C1621583	Administer
